Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine

NCT01148017 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01148017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01148017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2010
Completion date
April 30, 2013
Enrollment
433 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal meningitis